Cervical adenocarcinoma Trials in St. Louis, United States
Conditions / Cervical adenocarcinoma / St. Louis, United States
Cervical adenocarcinoma has been the subject of sustained clinical investigation across multiple research sites.
12 total trials for this combination
Showing top 10 of 12 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02257528 | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT02257528 | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02257528 | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |